References
- Ottonello L, Epstein AL, Mancini M, . Chimaeric Lym-1 monoclonal antibody-mediated cytolysis by neutrophils from G-CSF-treated patients: stimulation by GM-CSF and role of Fc gamma-receptors. Br J Cancer 2001;85:463–469.
- Keler T, Wallace PK, Vitale LA, . Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages. J Immunol 2000;164:5746–5752.
- Venugopal P, Sivaraman S, Huang XK, . Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res 2000;24:411–415.
- Berdel WE, Danhauser-Riedi S, Steinhauser G, . Various human hemopoietic growth factors (interleukin-3, GM-CSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor cells. Blood 1989;73:80–83.
- Grabstein KH, Urdal DL, Tushinski RJ, . Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986;232:506–508.
- Gillessen S, Naumov YN, Nieuwenhuis EE, . CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci USA 2003;100:8874–8879.
- Juweid ME, Wiseman GA, Vose JM, . Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005;23:4652–4661.
- Brusamolino E, Rusconi C, Montalbetti L, . Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006;91:496–502.
- Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
- Pfreundschuh M, Trumper L, Kloess M, . Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–641.
- The International Non Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non Hodgkin's lymphoma. N Engl J Med 1993;329:987–995.
- Chang JE, Seo S, Kim KM, . Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study. Clin Lymphoma Myeloma Leuk 2010;10:379–384.
- Gisselbrecht C, Glass B, Laurent G, . Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. J Clin Oncol 2011;29(Suppl.): Abstract 8004.